Archive Issue Details

Archive Issue Details Volume.2 ,Issue . 4

Manuscript Number
IJPRT-2023-11-060

Manuscript Title
Efgartigimod: The Saviour for Autoimmune Condition

Article Type
Review Article

Author Names

Snehal Chakorkar *
Avanti Todkar
Divya Kakade
Shantanu Date

Abstract
Efgartigimod (efgartigimodalfa-fcab, Vyvgart™) is a first-in-class neonatal Fc receptor antagonist being developed by argenx for the treatment of autoimmune diseases including myasthenia gravis. It used specifically in generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. Efgartigimod binds to the FcRn and inhibits its interaction with IgG, thereby reducing IgG recycling and increasing degradation of IgG and pathological auto antibodies, with

Keywords .
Efgartigimod, auto antibodies, Autoimmune, Immunoglobulins

Files
View PDF